Seek Returns

ABBV vs. BBIO: AbbVie vs. BridgeBio Pharma Stock Comparison

How do AbbVie (ABBV) and BridgeBio Pharma (BBIO) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

AbbVie (ABBV) and BridgeBio Pharma (BBIO) are both classified in the Biotechnology sub-industry within the broader Biotechnology industry, placing them in the closest GICS peer bucket.

Company profile comparison for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
Profile ItemABBVBBIO
NameAbbVie Inc.BridgeBio Pharma Inc.
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnologyBiotechnology
GICS Sub-IndustryBiotechnologyBiotechnology
Market Capitalization514.92 billion USD14.47 billion USD
CurrencyUSDUSD
ExchangeNYSENasdaq
Listing DateJanuary 2, 2013June 27, 2019
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

ABBV
BBIO
GSPC
Loading price history…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for AbbVie (ABBV) and BridgeBio Pharma (BBIO). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for AbbVie (ABBV) and BridgeBio Pharma (BBIO). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
Total Return (1Y)37.33%22.70%
Total Return (3Y, Annualized)32.74%40.97%
Total Return (5Y, Annualized)24.73%8.25%

Risk Profile

Drawdown History

ABBV
BBIO
GSPC
Loading price history…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for AbbVie (ABBV) and BridgeBio Pharma (BBIO). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
Volatility (1Y, Annualized)25.65%44.39%
Beta (5Y)0.210.93
Max Drawdown (5Y)-21.92%-89.79%
Avg. Volume (3M)4.76M2.68M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
ABBV and BBIO are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
Sharpe Ratio (1Y)1.290.41
Sortino Ratio (1Y)2.020.63

Profitability

ROE (TTM)

Neither AbbVie (ABBV) nor BridgeBio Pharma (BBIO) reports a ROE value for this period, so a direct comparison isn’t possible.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
ABBV
--

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
109.18%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
BBIO
--
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): Neither stock reports ROE, so the chart shows available benchmark boxes without value markers.

Net Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative net margin of -59.84%, usually indicating a net loss over the period. Meanwhile AbbVie (ABBV) reports 15.67%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max
18.05%
ABBV
15.67%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-59.84%

Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
BBIO
-59.84%
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

BridgeBio Pharma (BBIO) reports a negative operating margin of -3.30%, usually indicating that operating costs exceeded revenue at the operating-income line. Meanwhile AbbVie (ABBV) reports 39.59%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max
83.12%
ABBV
39.59%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-3.30%

Max
83.12%
Q3
14.77%
Median
0.00%
BBIO
-3.30%
Q1
-78.82%
Min
-207.40%
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
ROE (TTM)----
ROA (TTM)10.74%-13.97%
Net Margin (TTM)15.67%-59.84%
Operating Margin (TTM)39.59%-3.30%
Gross Margin (TTM)73.72%94.34%

Growth

Revenue Growth

BridgeBio Pharma (BBIO) at 126.26% sits in the top revenue growth quartile, while AbbVie (ABBV) at 8.57% is closer to the peer norm — faster top-line expansion for BBIO.

Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: AbbVie (ABBV) reports EPS growth of -0.84%, ranked against its industry; BridgeBio Pharma (BBIO) has no EPS growth figure this period.

Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
Revenue Growth (YoY)8.57%126.26%
Revenue Growth (3Y CAGR)1.75%86.30%
EPS Growth (YoY)-0.84%--
EPS Growth (3Y CAGR)-29.03%--

Financial Strength

Current Ratio (MRQ)

Both AbbVie (ABBV) at 0.87 and BridgeBio Pharma (BBIO) at 2.09 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ABBV
0.87
Min
0.10

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.09

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
BBIO
2.09
Min
0.10
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Neither AbbVie (ABBV) nor BridgeBio Pharma (BBIO) reports a debt-to-equity ratio value for this period, so a direct comparison isn’t possible.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
ABBV
--

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
BBIO
--
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): Neither stock reports debt-to-equity ratio, so the chart shows available benchmark boxes without value markers.

Financial Strength Metrics

Financial strength metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
Current Ratio (MRQ)0.872.09
Debt / Equity (MRQ)----
Net Debt / EBITDA2.21--

Dividends

Dividend Yield (TTM)

BridgeBio Pharma (BBIO) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile AbbVie (ABBV) reports a yield of 2.40%, ranking against industry peers normally.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV
2.40%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings; BridgeBio Pharma (BBIO) pays no dividend (payout 0.00%).

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV
117.35%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BBIO
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
Dividend Yield (TTM)2.40%0.00%
Dividend Payout Ratio (TTM)117.35%0.00%

Valuation

P/E Ratio (TTM)

An earnings multiple is available for just one side: AbbVie (ABBV) trades at 50.05 times trailing earnings, ranked against its peers, while BridgeBio Pharma (BBIO) has no P/E ratio this period.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max
85.34
ABBV
50.05
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

--

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
Min
0.07
BBIO
--
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): BBIO does not report P/E ratio, so it has no value marker; ABBV is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

P/S Ratio (TTM)

On P/S ratio, both AbbVie (ABBV) at 7.80 and BridgeBio Pharma (BBIO) at 15.31 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max
58.18
Q3
25.77
ABBV
7.80
Median
7.30
Q1
3.01
Min
0.01

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.31

Max
58.18
Q3
25.77
BBIO
15.31
Median
7.30
Q1
3.01
Min
0.01
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Both AbbVie (ABBV) at -112.34 and BridgeBio Pharma (BBIO) at -5.59 report negative P/B ratio values, meaning both companies have negative book equity — neither multiple is meaningful for valuation.

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
ABBV
-112.34

BBIO

Pharmaceuticals, Biotechnology & Life Sciences industry group

-5.59

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BBIO
-5.59
Min
-5.59
Loading chart…
AbbVie (ABBV) vs. BridgeBio Pharma (BBIO): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for AbbVie (ABBV) and BridgeBio Pharma (BBIO)
MetricABBVBBIO
P/E Ratio (TTM)50.05--
P/S Ratio (TTM)7.8015.31
P/B Ratio (MRQ)-112.34-5.59
Free Cash Flow Yield (TTM)3.44%-1.98%